Company / Financials
Protara Therapeutics, Inc. Financials
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$2.9M
FY2016 · 0.0% YoY
Net Income
-$3.3M
FY2016 · +57.8% YoY
Profit Margin
-113.4%
FY2016 · net income / revenue
ROE
-4.0%
FY2016 · return on equity
Total Assets
$43.5M
FY2016
Total Debt
-
FY2016
Equity
$82.5M
FY2016
ROA
-7.7%
FY2016 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.74 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$2.9M0.0% YoYNet Income HistoryProfit after all expenses and taxes-$3.3M+57.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$7.6M-6.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$4.1M+30.9% YoYR&D Expense HistoryResearch and development spending$6.4M+61.0% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense-EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$3.16+94.7% YoYShares Outstanding HistoryWeighted average diluted shares outstanding16.5M+0.3% YoYTotal Assets HistoryTotal value of all assets owned$43.5M-35.6% YoY